Healthcare companies by risk reading
Healthcare companies by risk reading: 1,695 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 21 October 2026.
Composite readings for 14,899 companies, recomputed 21 October 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Tsuruha Holdings Inc. 3391.T | 37 | Normal | Healthcare | Japan | 4 / 6 | $6.3B |
| MatsukiyoCocokara & Co. 3088.T | 41 | Elevated | Healthcare | Japan | 5 / 6 | $6.3B |
| Centessa Pharmaceuticals plc CNTA | 73 | Stretched | Healthcare | United Kingdom | 4 / 6 | $6.3B |
| Sinopharm Group Co. Ltd. 1099.HK | 49 | Elevated | Healthcare | China | 5 / 6 | $6.3B |
| Kiniksa Pharmaceuticals International plc. - Class A KNSA | 24 | Normal | Healthcare | United Kingdom | 4 / 6 | $6.2B |
| Alibaba Health Information Technology Limited 0241.HK | 46 | Elevated | Healthcare | Hong Kong | 5 / 6 | $6.2B |
| Amneal Pharmaceuticals Inc - Class A AMRX | 38 | Normal | Healthcare | United States | 6 / 6 | $6.2B |
| Rhythm Pharmaceuticals Inc RYTM | 55 | Elevated | Healthcare | United States | 6 / 6 | $6.1B |
| Ligand Pharmaceuticals Inc - Class B LGND | 31 | Normal | Healthcare | United States | 5 / 6 | $6.0B |
| Bausch + Lomb Corp BLCO | 63 | Stretched | Healthcare | Canada | 5 / 6 | $5.9B |
| Cochlear Limited COH.AX | 53 | Elevated | Healthcare | Australia | 4 / 6 | $5.9B |
| Asahi Intecc Co., Ltd. 7747.T | 25 | Normal | Healthcare | Japan | 5 / 6 | $5.9B |
| SINOPHARM GROUP 1/5/O.N. X2S1 | 51 | Elevated | Healthcare | China | 5 / 6 | $5.8B |
| Ypsomed Holding AG YPSN.SW | 27 | Normal | Healthcare | Switzerland | 5 / 6 | $5.7B |
| Doximity Inc - Class A DOCS | 25 | Normal | Healthcare | United States | 6 / 6 | $5.7B |
| Convatec Group PLC CTEC.L | 42 | Elevated | Healthcare | United Kingdom | 5 / 6 | $5.6B |
| Teleflex Incorporated TFX | 65 | Stretched | Healthcare | United States | 6 / 6 | $5.5B |
| GRAIL Inc GRAL | 37 | Normal | Healthcare | United States | 5 / 6 | $5.5B |
| Radnet Inc RDNT | 58 | Elevated | Healthcare | United States | 6 / 6 | $5.4B |
| Haemonetics Corp HAE | 45 | Elevated | Healthcare | United States | 5 / 6 | $5.4B |
| Waystar Holding Corp WAY | 38 | Normal | Healthcare | United States | 4 / 6 | $5.4B |
| Merit Medical Systems Inc MMSI | 41 | Elevated | Healthcare | United States | 6 / 6 | $5.4B |
| Mirum Pharmaceuticals Inc MIRM | 45 | Elevated | Healthcare | United States | 4 / 6 | $5.3B |
| Cg Oncology Inc CGON | 35 | Normal | Healthcare | United States | 5 / 6 | $5.3B |
| Galenica Sante AG GALE | 43 | Elevated | Healthcare | Switzerland | 5 / 6 | $5.3B |
| Apellis Pharmaceuticals Inc APLS | 23 | Normal | Healthcare | United States | 5 / 6 | $5.3B |
| Stevanato Group Spa STVN | 45 | Elevated | Healthcare | Italy | 5 / 6 | $5.2B |
| PTC Therapeutics Inc PTCT | 14 | Contained | Healthcare | United States | 5 / 6 | $5.1B |
| Sotera Health Company SHC | 37 | Normal | Healthcare | United States | 6 / 6 | $5.0B |
| RemeGen Co., Ltd. 9995.HK | 31 | Normal | Healthcare | China | 5 / 6 | $5.0B |
| MiniMed Group, Inc. MMED | 57 | Elevated | Healthcare | United States | 5 / 6 | $5.0B |
| Concentra Group Holdings Parent Inc CON | 42 | Elevated | Healthcare | United States | 5 / 6 | $4.9B |
| CRISPR Therapeutics AG CRSP | 47 | Elevated | Healthcare | Switzerland | 4 / 6 | $4.8B |
| Travere Therapeutics Inc TVTX | 57 | Elevated | Healthcare | United States | 4 / 6 | $4.8B |
| Billiontoone Inc - Class A BLLN | 33 | Normal | Healthcare | United States | 5 / 6 | $4.7B |
| Option Care Health Inc OPCH | 35 | Normal | Healthcare | United States | 5 / 6 | $4.7B |
| Shanghai Junshi Biosciences Co., Ltd. 688180.SS | 51 | Elevated | Healthcare | China | 5 / 6 | $4.6B |
| 3SBio Inc. 1530.HK | 17 | Contained | Healthcare | China | 5 / 6 | $4.6B |
| Amicus Therapeutics Inc FOLD | 35 | Normal | Healthcare | United States | 5 / 6 | $4.5B |
| Hikma Pharmaceuticals PLC H5P | 43 | Elevated | Healthcare | United Kingdom | 5 / 6 | $4.5B |
| LifeStance Health Group Inc LFST | 33 | Normal | Healthcare | United States | 5 / 6 | $4.5B |
| Heartflow Inc HTFL | 67 | Stretched | Healthcare | United States | 6 / 6 | $4.4B |
| Hikma Pharmaceuticals PLC HIK | 43 | Elevated | Healthcare | United Kingdom | 5 / 6 | $4.4B |
| Ansell Ltd ANN | 31 | Normal | Healthcare | Australia | 3 / 6 | $4.4B |
| Integer Holdings Corp ITGR | 38 | Normal | Healthcare | United States | 6 / 6 | $4.3B |
| LivaNova PLC LIVN | 39 | Normal | Healthcare | United Kingdom | 6 / 6 | $4.3B |
| DIASORIN DIA.MI | 48 | Elevated | Healthcare | Italy | 4 / 6 | $4.2B |
| Dianthus Therapeutics Inc DNTH | 70 | Stretched | Healthcare | United States | 5 / 6 | $4.1B |
| Medicover AB (publ) MCOV-B | 39 | Normal | Healthcare | Sweden | 3 / 6 | $4.1B |
| ANSELL (UNSP.ADRS)/4 PD1 | 50 | Elevated | Healthcare | Australia | 4 / 6 | $4.1B |
| MediPal Holdings Corporation 7459.T | 52 | Elevated | Healthcare | Japan | 4 / 6 | $4.0B |
| ICU Medical Inc ICUI | 56 | Elevated | Healthcare | United States | 6 / 6 | $4.0B |
| Aspen Pharmacare Holdings Limited LDZA | 53 | Elevated | Healthcare | South Africa | 5 / 6 | $4.0B |
| Arcutis Biotherapeutics Inc ARQT | 37 | Normal | Healthcare | United States | 6 / 6 | $4.0B |
| Indivior Plc INDV | 43 | Elevated | Healthcare | United States | 5 / 6 | $4.0B |
| Catalyst Pharmaceuticals Inc CPRX | 17 | Contained | Healthcare | United States | 4 / 6 | $3.9B |
| Adaptive Biotechnologies Corp ADPT | 46 | Elevated | Healthcare | United States | 6 / 6 | $3.8B |
| National Healthcare Corp NHC | 29 | Normal | Healthcare | United States | 5 / 6 | $3.7B |
| Relay Therapeutics Inc RLAY | 46 | Elevated | Healthcare | United States | 4 / 6 | $3.7B |
| Siegfried Holding Ltd SFZN | 53 | Elevated | Healthcare | Switzerland | 4 / 6 | $3.7B |
| Tecan Group AG TECN | 63 | Stretched | Healthcare | Switzerland | 5 / 6 | $3.7B |
| China Resources Pharmaceutical Group Limited 3320.HK | 49 | Elevated | Healthcare | Hong Kong | 5 / 6 | $3.7B |
| Ottobock SE & Co. KGaA OBCK | 41 | Elevated | Healthcare | Germany | 5 / 6 | $3.7B |
| AbCellera Biologics Inc ABCL | 80 | Acute | Healthcare | Canada | 5 / 6 | $3.7B |
| Telix Pharmaceuticals Ltd TLX | 48 | Elevated | Healthcare | Australia | 4 / 6 | $3.6B |
| Envista Holdings Corp NVST | 42 | Elevated | Healthcare | United States | 5 / 6 | $3.6B |
| Organon & Company OGN | 47 | Elevated | Healthcare | United States | 6 / 6 | $3.6B |
| iRhythm Technologies Inc IRTC | 60 | Stretched | Healthcare | United States | 4 / 6 | $3.6B |
| Amplifon S.p.A AMP.MI | 47 | Elevated | Healthcare | Italy | 3 / 6 | $3.6B |
| Simcere Pharmaceutical Group Limited 2096.HK | 32 | Normal | Healthcare | China | 5 / 6 | $3.6B |
| Shanghai Henlius Biotech, Inc. 2696.HK | 33 | Normal | Healthcare | China | 5 / 6 | $3.6B |
| Santen Pharmaceutical Co., Ltd. 4536.T | 45 | Elevated | Healthcare | Japan | 3 / 6 | $3.5B |
| Veracyte Inc VCYT | 40 | Elevated | Healthcare | United States | 6 / 6 | $3.5B |
| Legend Biotech Corp LEGN | 41 | Elevated | Healthcare | United States | 5 / 6 | $3.5B |
| Caredx Inc CDNA | 49 | Elevated | Healthcare | United States | 6 / 6 | $3.5B |
| Imricor Medical Systems, Inc. IMR.AX | 80 | Acute | Healthcare | United States | 4 / 6 | $3.4B |
| Acadia Pharmaceuticals Inc ACAD | 30 | Normal | Healthcare | United States | 6 / 6 | $3.4B |
| Tango Therapeutics Inc TNGX | 36 | Normal | Healthcare | United States | 5 / 6 | $3.4B |
| Xenon Pharmaceuticals Inc XENE | 67 | Stretched | Healthcare | Canada | 4 / 6 | $3.4B |
| Pulse Biosciences Inc PLSE | 65 | Stretched | Healthcare | United States | 4 / 6 | $3.4B |
| Laboratorios Farmaceuticos ROVI ROVI | 35 | Normal | Healthcare | Spain | 5 / 6 | $3.3B |
| XtalPi Holdings Limited 2228.HK | 46 | Elevated | Healthcare | China | 5 / 6 | $3.2B |
| COSMOS Pharmaceutical Corporation 3349.T | 46 | Elevated | Healthcare | Japan | 5 / 6 | $3.2B |
| China Medical System Holdings Limited 0867.HK | 52 | Elevated | Healthcare | Hong Kong | 5 / 6 | $3.2B |
| Warby Parker Inc - Class A WRBY | 36 | Normal | Healthcare | United States | 5 / 6 | $3.1B |
| Keymed Biosciences Inc. 2162.HK | 46 | Elevated | Healthcare | China | 5 / 6 | $3.1B |
| Liquidia Corp LQDA | 53 | Elevated | Healthcare | United States | 5 / 6 | $3.0B |
| Sugi Holdings Co.,Ltd. 7649.T | 37 | Normal | Healthcare | Japan | 5 / 6 | $3.0B |
| Tarsus Pharmaceuticals Inc TARS | 52 | Elevated | Healthcare | United States | 6 / 6 | $3.0B |
| Oxford Nanopore Technologies Ltd ONT | 49 | Elevated | Healthcare | United Kingdom | 6 / 6 | $3.0B |
| Ideaya Biosciences Inc IDYA | 35 | Normal | Healthcare | United States | 5 / 6 | $3.0B |
| Ambu A/S AMBU-B | 47 | Elevated | Healthcare | Denmark | 3 / 6 | $2.9B |
| Virbac SA VIRP | 38 | Normal | Healthcare | France | 5 / 6 | $2.9B |
| CLICKS GROUP LTD RC-01 N1C | 43 | Elevated | Healthcare | South Africa | 5 / 6 | $2.9B |
| InSilico Medicine Cayman TopCo 3696.HK | 54 | Elevated | Healthcare | Hong Kong | 5 / 6 | $2.9B |
| Privia Health Group Inc PRVA | 40 | Elevated | Healthcare | United States | 5 / 6 | $2.8B |
| Atricure Inc ATRC | 44 | Elevated | Healthcare | United States | 6 / 6 | $2.8B |
| Sunshine Lake Pharma Co., Ltd. 6887.HK | 47 | Elevated | Healthcare | China | 5 / 6 | $2.8B |
| Arcus Biosciences Inc RCUS | 73 | Stretched | Healthcare | United States | 5 / 6 | $2.8B |
| Biocytogen Pharmaceuticals (Beijing) Co., Ltd. 2315.HK | 19 | Contained | Healthcare | China | 5 / 6 | $2.8B |
By sector
Industrials 3,117Technology 2,425Consumer Cyclical 2,231Healthcare 1,695Consumer Defensive 1,055Basic Materials 1,055Real Estate 1,011Communication Services 956Energy 487Utilities 343Financial Services 90
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.